Clinical Trial Results:
Patiromer-facilitated, dose-escalation of mineralocorticoid antagonists for the management of worsening congestion in people with heart failure and hyperkalaemia.
A Phase IV, registry-based, randomised, controlled, open-label trial investigating the potential for patiromer-facilitated use of higher doses of mineralocorticoid antagonists in addition to standard care (compared to standard care alone) to improve congestion, well-being, morbidity and mortality.
Summary
|
|
EudraCT number |
2018-003662-14 |
Trial protocol |
GB |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
01 Sep 2024
|
First version publication date |
01 Sep 2024
|
Other versions |
|
Summary report(s) |
RELIEHF_summary_of_results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.